Buch, Englisch, 356 Seiten, Format (B × H): 157 mm x 236 mm, Gewicht: 680 g
Buch, Englisch, 356 Seiten, Format (B × H): 157 mm x 236 mm, Gewicht: 680 g
ISBN: 978-0-85404-144-2
Verlag: RSC Publishing
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Preface;
1 - Fragment Descriptors in SAR/QSAR/QSPR studies, molecular similarity analysis and in virtual screening;
Introduction;
Historical survey;
Main characteristics of Fragment Descriptors;
Types of Fragments;
Simple Fixed Types;
WLN and SMILES Fragments;
Atom-Centered Fragments;
Bond-Centered Fragments;
Maximum Common Substructures;
Atom Pairs and Topological Multiplets;
Substituents and Molecular Frameworks;
Basic Subgraphs;
Mined Subgraphs;
Random Subgraphs;
Library Subgraphs;
Fragments describing supramolecular systems and chemical reactions;
Storage of fragments' information;
Fragment's Connectivity;
Generic Graphs;
Labeling Atoms;
Application in Virtual Screening and In Silico Design;
Filtering;
Similarity Search;
SAR Classification (Probabilistic) Models;
QSAR/QSPR Regression Models;
In Silico Design;
Limitations of Fragment Descriptors;
Conclusion;
2 - Topological Pharmacophores;
Introduction;
3D pharmacophore models and descriptors;
Topological pharmacophores;
Topological pharmacophores from 2D-aligments;
Topological pharmacophores from 2D pharmacophore fingerprints;
Topological index-based 'pharmacophores'?;
Topological pharmacophores from 2D-aligments;
Topological pharmacophores from pharmacophore fingerprints;
Topological pharmacophore pair fingerprints;
Topological pharmacophore triplets;
Similarity searching with pharmacophore fingerprints - Technical Issues;
Similarity searching with pharmacophore fingerprints - Some Examples;
Machine-learning of Topological Pharmacophores from Fingerprints;
Topological index-based 'pharmacophores'?;
Conclusions;
3 - Pharmacophore-based Virtual Screening in Drug Discovery;
Introduction;
Virtual Screening Methods;
Chemical Feature-based Pharmacophores;
The Term "3D Pharmacophore";
Feature Definitions and Pharmacophore Representation;
Hydrogen bonding interactions;
Lipophilic areas;
Aromatic interactions;
Charge-transfer interactions;
Customization and definition of new features;
Current super-positioning techniques for aligning 3D pharmacophores and molecules;
Generation and Use of Pharmacophore Models;
Ligand-based Pharmacophore Modeling;
Structure-based Pharmacophore Modeling;
Inclusion of Shape Information;
Qualitative vs. Quantitative Pharmacophore Models;
Validation of Models for Virtual Screening;
Application of Pharmacophore Models in Virtual Screening;
Pharmacophore Models as Part of a Multi-Step Screening Approach;
Antitarget and ADME(T) Screening Using Pharmacophores;
Pharmacophore Models for Activity Profiling and Parallel Virtual Screening;
Pharmacophore Method Extensions and Comparisons to Other Virtual Screening Methods;
Topological Fingerprints;
Shape-based Virtual Screening;
Docking Methods;
Pharmacophore Constraints Used in Docking;
Further Reading;
Summary and Conclusion;
4 - Molecular Similarity Analysis in Virtual Screening;
Ligand-Based Virtual Screening;
Foundations of Molecular Similarity Analysis;
Molecular Similarity and Chemical Spaces;
Similarity Measures;
Activity Landscapes;
Analyzing the Nature of Structure-Activity Relationships;
Relationships between different SARs;
SARs and target-ligand interactions;
Qualitative SAR characterization;
Quantitative SAR characterization;
Implications for molecular similarity analysis and virtual screening;
Strengths and Limitations of Similarity Methods;
Conclusion and Future Perspectives;
5 - Molecular Field Topology Analysis in drug design and virtual screening;
Introduction: local molecular parameters in QSAR, drug design and virtual screening;
Supergraph-based QSAR models;
Rationale and history;
Molecular Field Topology Analysis (MFTA);
General principles;
Local molecular descriptors: facets of ligand-biotarget interaction;
Construction of molecular supergraph;
Formation of descriptor matrix;
Statistical analysis;
Applicability control;
From MFTA model to drug design and virtual screening;
MFTA models in biotarget and drug action analysis;
MFTA models in virtual screening;
MFTA-based virtual screening of compound databases;
MFTA-based virtual screening of generated structure libraries;
Conclusion;
6 - Probabilistic approaches in activity prediction;
Introduction;
Biological Activity;
Dose-Effect Relationships;
Experimental Data;
Probabilistic Ligand-Based Virtual Screening Methods;
Preparation of Training Sets;
Creation of Evaluation Sets;
Mathematical Approaches;
Evaluation of Prediction Accuracy;
Single-Targeted vs. Multi-Targeted Virtual Screening;
PASS Approach;
Biological Activities Predicted by PASS;
Chemical Structure Description in PASS;
SAR Base;
Algorithm of Activity Spectrum Estimation;
Interpretation of Prediction Results;
Selection of the Most Prospective Compounds;
Conclusions;
7 - Fragment-based de novo design of druglike molecules;
Introduction;From Molecules to Fragments;
From Fragments to Molecules;
Scoring the Design;
Conclusions and Outlook;
8 - Early ADME/T predictions: a toy or a tool?;
Introduction;
Which properties are important for early drug discovery?;
Physico-chemical profiling;
Lipophilicity;
Solubility;
Data availability and accuracy;
Models;
Why models don't work: the challenge of the Applicability Domain;
AD based on similarity in the descriptor space;
AD based on similarity in the property-based space;
How reliable are predictions of physico-chemical properties?;
Available Data for ADME/T biological properties;
Absorption;
Data;
Models;
Distribution;
Data;
Models;
The usefulness of ADME/T models is limited by available data;
Conclusions;
9 - Compound Library Design - Principles and Applications;
Introduction to Compound Library Design;
Methods for Compound Library Design;
Design for Specific Biological Activities;
Similarity Guided Design of Targeted Libraries;
Diversity Based Design of General Screening Libraries;
Pharmacophore Guided Design of Focused Compound Libraries;
QSAR Based Targeted Library Design;
Protein Structure Based Methods for Compound Library Design;
Design for Developability or Drug-likeness;
Rule & Alert Based Approaches;
QSAR Based ADMET Models;
Undesirable Functionality Filters;
Design for Multiple Objectives and Targets Simultaneously;
Concluding Remarks;
10 - Integrated Chemo- and Bioinformatics Approaches to Virtual Screening;
Introduction;
Availability of large compound collections for virtual screening;
NIH Molecular Libraries Roadmap Initiative and the PubChem database;
Other chemical databases in public domain;
Structure based virtual screening;
Major methodologies;
Challenges and limitations of current approaches;
The implementation of cheminformatics concepts in structure based virtual screening;
Predictive QSAR models as virtual screening tools;
Critical Importance of model validation;
Applicability domains and QSAR model acceptability criteria;
Predictive QSAR modeling workflow;
Examples of application;
Structure based chemical descriptors of protein ligand interface: the EnTESS method;
Derivation of the EnTESS descriptors;
Validation of the EnTESS descriptors for binding affinity prediction;
Structure based cheminformatics approach to virtual screening: the CoLiBRI method;
The representation of three-dimensional active sites in multidimensional chemistry space;
The mapping between chemistry spaces of active sites and ligands;
Summary and Conclusions